Page 213 - Read Online

Galletti et al. Using CTCs in prostate cancer

70. Liu X, Ledet E, Li D, Dotiwala A, Steinberger A, Feibus A, Li J, Qi immunology advancements. Biomark Cancer 2016;8:15-33.
Y, Silberstein J, Lee B, Dong Y, Sartor O, Zhang H. A whole blood 80. Galletti G, Matov A, Beltran H, Fontugne J, Miguel Mosquera J,
assay for AR-V7 and ARv567es in patients with prostate cancer. J Cheung C, MacDonald TY, Sung M, O’Toole S, Kench JG, Suk
Urol 2016;196:1758-63. Chae S, Kimovski D, Tagawa ST, Nanus DM, Rubin MA, Horvath
71. Qu F, Xie W, Nakabayashi M, Zhang H, Jeong SH, Wang X, Komura LG, Giannakakou P, Rickman DS. ERG induces taxane resistance in
K, Sweeney CJ, Sartor O, Lee GM, Kantoff PW. Association of AR- castration-resistant prostate cancer. Nat Commun 2014;5:5548.
V7 and prostate specific antigen RNA levels in blood with efficacy of 81. Reig O, Marin-Aguilera M, Carrera G, Jimenez N, Pare L, Garcia-
abiraterone acetate and enzalutamide treatment in men with prostate Recio S, Gaba L, Pereira MV, Fernandez P, Prat A, Mellado B.
cancer. Clin Cancer Res 2017;23:726-34. TMPRSS2-ERG in blood and docetaxel resistance in metastatic
72. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun castration-resistant prostate cancer. Eur Urol 2016;70:709-13.
XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, 82. Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK,
Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion Fleisher M, Sander C, Sawyers CL, Scher HI. Distinct patterns of
of TMPRSS2 and ETS transcription factor genes in prostate cancer. dysregulated expression of enzymes involved in androgen synthesis
Science 2005;310:644-8. and metabolism in metastatic prostate cancer tumors. Cancer Res
73. Cancer Genome Atlas Research Network. The molecular taxonomy of 2012;72:6142-52.
primary prostate cancer. Cell 2015;163:1011-25. 83. Wang Y, Shi J, Chai K, Ying X, Zhou BP. The role of snail in EMT and
74. Kulda V, Topolcan O, Kucera R, Kripnerova M, Srbecka K, Hora tumorigenesis. Curr Cancer Drug Targets 2013;13:963-72.
M, Hes O, Klecka J, Babuska V, Rousarova M, Benson V, Pesta M. 84. Ware KE, Somarelli JA, Schaeffer D, Li J, Zhang T, Park S, Patierno
Prognostic significance of TMPRSS2-ERG fusion gene in prostate SR, Freedman J, Garcia-Blanco MA, Armstrong AJ. Snail promotes
cancer. Anticancer Res 2016;36:4787-93. resistance to enzalutamide through regulation of androgen receptor
75. McDaniel AS, Ferraldeschi R, Krupa R, Landers M, Graf R, Louw J, activity in prostate cancer. Oncotarget 2016;7:50507-21.
Jendrisak A, Bales N, Marrinucci D, Zafeiriou Z, Flohr P, Sideris S, 85. Li YM, Xu SC, Li J, Han KQ, Pi HF, Zheng L, Zuo GH, Huang XB,
Crespo M, Figueiredo I, Mateo J, de Bono JS, Dittamore R, Tomlins Li HY, Zhao HZ, Yu ZP, Zhou Z, Liang P. Epithelial-mesenchymal
SA, Attard G. Phenotypic diversity of circulating tumour cells in transition markers expressed in circulating tumor cells in hepatocellular
patients with metastatic castration-resistant prostate cancer. BJU Int
2016; doi: 10.1111/bju.13631. carcinoma patients with different stages of disease. Cell Death Dis
76. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A’Hern R, 2013;4:e831.
Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche 86. Chen CL, Mahalingam D, Osmulski P, Jadhav RR, Wang CM, Leach
G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, RJ, Chang TC, Weitman SD, Kumar AP, Sun L, Gaczynska ME,
Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen Thompson IM, Huang TH. Single-cell analysis of circulating tumor
LW, de Bono JS. Characterization of ERG, AR and PTEN gene status cells identifies cumulative expression patterns of EMT-related genes
in circulating tumor cells from patients with castration-resistant in metastatic prostate cancer. Prostate 2013;73:813-26.
prostate cancer. Cancer Res 2009;69:2912-8. 87. Beltran H, Jendrisak A, Landers M, Mosquera JM, Kossai M,
77. Attard G, de Bono JS, Logothetis CJ, Fizazi K, Mukherjee SD, Louw J, Krupa R, Graf RP, Schreiber NA, Nanus DM, Tagawa ST,
Joshua AM, Schrijvers D, van den Eertwegh AJ, Li W, Molina A, Marrinucci D, Dittamore R, Scher HI. The initial detection and partial
Griffin TW, Kheoh T, Ricci DS, Zelinsky K, Rathkopf DE, Scher HI, characterization of circulating tumor cells in neuroendocrine prostate
Ryan CJ. Improvements in radiographic progression-free survival cancer. Clin Cancer Res 2016;22:1510-9.
stratified by erg gene status in metastatic castration-resistant prostate 88. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R,
cancer patients treated with abiraterone acetate. Clin Cancer Res Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja
2015;21:1621-7. H, Heller G, Fleisher M, Scher HI. Circulating tumor cell analysis
78. Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, in patients with progressive castration-resistant prostate cancer. Clin
Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI. TMPRSS2- Cancer Res 2007;13:2023-9.
ERG status in circulating tumor cells as a predictive biomarker of 89. Paris PL, Kobayashi Y, Zhao Q, Zeng W, Sridharan S, Fan T, Adler
sensitivity in castration-resistant prostate cancer patients treated with HL, Yera ER, Zarrabi MH, Zucker S, Simko J, Chen WT, Rosenberg
abiraterone acetate. Eur Urol 2011;60:897-904. J. Functional phenotyping and genotyping of circulating tumor cells
79. Gaudreau PO, Stagg J, Soulieres D, Saad F. The present and future from patients with castration resistant prostate cancer. Cancer Lett
of biomarkers in prostate cancer: proteomics, genomics, and 2009;277:164-73.

Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ September 27, 2017 205